BlueCrest Capital Management Ltd Invests $531,000 in Bio-Techne Corp (TECH)

BlueCrest Capital Management Ltd purchased a new stake in shares of Bio-Techne Corp (NASDAQ:TECH) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,523 shares of the biotechnology company’s stock, valued at approximately $531,000.

Several other institutional investors have also recently made changes to their positions in TECH. UBS Asset Management Americas Inc. lifted its holdings in shares of Bio-Techne Corp by 11.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 24,224 shares of the biotechnology company’s stock valued at $2,462,000 after buying an additional 2,453 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Bio-Techne Corp by 5.8% during the 1st quarter. Prudential Financial Inc. now owns 23,225 shares of the biotechnology company’s stock valued at $2,361,000 after buying an additional 1,278 shares during the last quarter. Stifel Financial Corp lifted its holdings in shares of Bio-Techne Corp by 11.4% during the 1st quarter. Stifel Financial Corp now owns 8,928 shares of the biotechnology company’s stock valued at $908,000 after buying an additional 913 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Bio-Techne Corp by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 153,397 shares of the biotechnology company’s stock valued at $15,592,000 after buying an additional 3,708 shares during the last quarter. Finally, Advantus Capital Management Inc lifted its holdings in shares of Bio-Techne Corp by 3.0% during the 1st quarter. Advantus Capital Management Inc now owns 4,777 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 140 shares during the last quarter. Institutional investors and hedge funds own 98.40% of the company’s stock.

TECH has been the subject of several research reports. BidaskClub upgraded Bio-Techne Corp from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Zacks Investment Research upgraded Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Thursday, July 6th. Wells Fargo & Company initiated coverage on Bio-Techne Corp in a report on Thursday, July 13th. They set a “market perform” rating for the company. Finally, Deutsche Bank AG lifted their price target on Bio-Techne Corp from $130.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $128.75.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/17/bluecrest-capital-management-ltd-invests-531000-in-bio-techne-corp-tech.html.

Shares of Bio-Techne Corp (TECH) opened at 122.54 on Tuesday. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of 60.36 and a beta of 0.76. The company has a 50-day moving average price of $121.82 and a 200 day moving average price of $114.44. Bio-Techne Corp has a 12-month low of $95.68 and a 12-month high of $125.40.

Bio-Techne Corp (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.10. The firm had revenue of $156.60 million during the quarter, compared to the consensus estimate of $150.25 million. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. The business’s revenue was up 16.2% compared to the same quarter last year. During the same period last year, the company earned $0.92 earnings per share. Equities research analysts expect that Bio-Techne Corp will post $3.99 earnings per share for the current fiscal year.

In other news, Director Karen A. Holbrook sold 1,059 shares of the firm’s stock in a transaction that occurred on Wednesday,

Several other institutional investors have also recently made changes to their positions in TECH. UBS Asset Management Americas Inc. lifted its holdings in shares of Bio-Techne Corp by 11.3% during the 1st quarter. UBS Asset Management Americas Inc. now owns 24,224 shares of the biotechnology company’s stock valued at $2,462,000 after buying an additional 2,453 shares during the last quarter. Prudential Financial Inc. lifted its holdings in shares of Bio-Techne Corp by 5.8% during the 1st quarter. Prudential Financial Inc. now owns 23,225 shares of the biotechnology company’s stock valued at $2,361,000 after buying an additional 1,278 shares during the last quarter. Stifel Financial Corp lifted its holdings in shares of Bio-Techne Corp by 11.4% during the 1st quarter. Stifel Financial Corp now owns 8,928 shares of the biotechnology company’s stock valued at $908,000 after buying an additional 913 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Bio-Techne Corp by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 153,397 shares of the biotechnology company’s stock valued at $15,592,000 after buying an additional 3,708 shares during the last quarter. Finally, Advantus Capital Management Inc lifted its holdings in shares of Bio-Techne Corp by 3.0% during the 1st quarter. Advantus Capital Management Inc now owns 4,777 shares of the biotechnology company’s stock valued at $486,000 after buying an additional 140 shares during the last quarter. Institutional investors and hedge funds own 98.40% of the company’s stock.

TECH has been the subject of several research reports. BidaskClub upgraded Bio-Techne Corp from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Zacks Investment Research upgraded Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 price target for the company in a report on Thursday, July 6th. Wells Fargo & Company initiated coverage on Bio-Techne Corp in a report on Thursday, July 13th. They set a “market perform” rating for the company. Finally, Deutsche Bank AG lifted their price target on Bio-Techne Corp from $130.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $128.75.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/17/bluecrest-capital-management-ltd-invests-531000-in-bio-techne-corp-tech.html.

Shares of Bio-Techne Corp (TECH) opened at 122.54 on Tuesday. The firm has a market capitalization of $4.58 billion, a price-to-earnings ratio of 60.36 and a beta of 0.76. The company has a 50-day moving average price of $121.82 and a 200 day moving average price of $114.44. Bio-Techne Corp has a 12-month low of $95.68 and a 12-month high of $125.40.

Bio-Techne Corp (NASDAQ:TECH) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.10. The firm had revenue of $156.60 million during the quarter, compared to the consensus estimate of $150.25 million. Bio-Techne Corp had a return on equity of 14.19% and a net margin of 12.93%. The business’s revenue was up 16.2% compared to the same quarter last year. During the same period last year, the company earned $0.92 earnings per share. Equities research analysts expect that Bio-Techne Corp will post $3.99 earnings per share for the current fiscal year.

In other news, Director Karen A. Holbrook sold 1,059 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $121.73, for a total value of $128,912.07. Following the completion of the sale, the director now directly owns 914 shares of the company’s stock, valued at $111,261.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 1,359 shares of company stock valued at $164,632. Corporate insiders own 3.40% of the company’s stock.

Bio-Techne Corp Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply